Biotech Values

[WorstLuck]

the cost of a phase 3 is also a factor when evaluating a deal as you know.

https://www.durect.com/2024/09/durect-corporation-announces-phase-3-registrational-trial-design-for-larsucosterol-in-alcohol-associated-hepatitis/

The cost was thought to be around 20M in industry reports. Which, one might argue, means BHC is really rolling the dice here if costs to approval are in the 100M range.

Have fun with that too!